Hyland's Argues Class Action Trips On State Laws Despite 'Artful Pleading'
This article was originally published in The Tan Sheet & The Rose Sheet
Hyland’s says a class action complaint alleging deceptive business practices and false advertising for its baby products is not suitable to represent a class of consumers outside New York. But the plaintiffs argue that the issue over class suitability should be considered during the certification stage.
You may also be interested in...
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
A federal judge rejected an argument that FDA’s regulation of homeopathic drugs pre-empts a state consumer protection law.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.